Merrimack Pharmaceuticals CEO Robert Mulroy says the traditional approach to cancer — making drugs that go after certain proteins — is "fundamentally flawed," according to the Forbes' Treatments blog's Robert Langreth. Merrimack is now working with Sanofi-Aventis to develop cancer drugs using the principles of systems biology.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.